Multiple sclerosis (MS) is a neurodegenerative disease associated with inflammatory
demyelination and astroglial activation, with neuronal and axonal damage as the leading …

Biomarkers in body fluids could help to predict and monitor neurological decline in people
with multiple sclerosis (MS). We discuss markers for axonal damage in body fluids in people …

Background Tau and β-amyloid (Aβ) are proposed diagnostic biomarkers for Alzheimer
disease (AD). Previous studies report their relationship to clinical diagnoses of AD and other …

Objective: To test whether biomarkers for axonal degeneration correlated with clinical
subtypes and were of use in predicting progression of ALS. Methods: Patients with ALS (n …

Multiple sclerosis is a debilitating disease of the central nervous system that has been
characteristically classified as an immune‐mediated destruction of myelin, the protective …

Alzheimer disease is a complex neurodegenerative dementing illness. It has become a
major public health problem because of its increasing prevalence, long duration, high cost of …

Cognitive impairment (CI) is a frequent and disabling symptom in Multiple Sclerosis (MS).
Axonal damage may contribute to CI development from early stages. Nevertheless, no …

Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord that
predominantly affects white matter. MS has a variable clinical presentation and has no …

Nowadays, there is a need for reliable fluid biomarkers to improve differential diagnosis,
prognosis, and the prediction of treatment response, particularly in the management of …

The aim was to quantify tau protein and β-amyloid (Aβ42) in the CSF of patients with
sporadic Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), and controls. Double …